Liquidia Co. (NASDAQ:LQDA – Get Rating) was the recipient of a large decline in short interest during the month of February. As of February 28th, there was short interest totalling 2,390,000 shares, a decline of 8.8% from the February 13th total of 2,620,000 shares. Based on an average daily volume of 505,800 shares, the days-to-cover ratio is currently 4.7 days.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. Caligan Partners LP acquired a new position in Liquidia during the fourth quarter worth approximately $64,825,000. BlackRock Inc. increased its holdings in shares of Liquidia by 1.2% during the 3rd quarter. BlackRock Inc. now owns 3,096,689 shares of the company’s stock worth $16,845,000 after buying an additional 37,518 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Liquidia by 6.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,579,285 shares of the company’s stock worth $14,030,000 after buying an additional 154,722 shares during the period. State Street Corp boosted its holdings in Liquidia by 2.1% in the third quarter. State Street Corp now owns 1,478,953 shares of the company’s stock valued at $8,046,000 after acquiring an additional 30,742 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in Liquidia by 105.5% during the third quarter. Two Sigma Advisers LP now owns 917,700 shares of the company’s stock valued at $4,992,000 after acquiring an additional 471,100 shares during the period. 32.64% of the stock is currently owned by hedge funds and other institutional investors.
Liquidia Trading Down 2.5 %
NASDAQ LQDA opened at $6.36 on Thursday. The company has a market capitalization of $410.22 million, a PE ratio of -7.76 and a beta of 0.11. The business’s 50-day moving average price is $6.83 and its 200 day moving average price is $5.96. Liquidia has a twelve month low of $3.26 and a twelve month high of $8.79.
Analyst Upgrades and Downgrades
Liquidia Company Profile
Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.
- Get a free copy of the StockNews.com research report on Liquidia (LQDA)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.